BioTech/Drugs - New York, NY, US
Founded in July 2016 and headquartered in Brooklyn, New York, Concarlo is a precision-medicine oncology company focused on diagnosing and treating cancer with an innovative approach to targeting a unique cellular pathway - p27Kip1. Concarlo's novel IpY therapeutic will be the first inhibitor to solve the CDK2 resistance issue, the first therapeutic to target p27 and the first to inhibit CDK4 and CDK2 simulataneously.
Rackspace Email
WordPress.org
Google Font API
GoDaddy Hosting
Mobile Friendly
YouTube